Gait Disorders, NeurologicNCT04024085
Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition in Multiple Sclerosis
An observational study of Gait Disorders, Neurologic and Urinary Incontinence, Urge, run by Gérard Amarenco at 1 site in France.
Trial summary
The aim of the study is to create a specific test to assess the global time required to go to the toilet and to perform micturition, at the moment the patient decides to urinate in multiple sclerosis population, and to assess its reliability. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gait Disorders, Neurologic, Urinary Incontinence, Urge, Multiple Sclerosis
- What is being tested?
- completion of the test created Time to be Ready to Void
- How many people
- 70 participants
- Where
- 1 siteFrance
- Study dates
- 13 Mar 2019to 31 Jul 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with multiple sclerosis who were consulting in neuro-urology department
Who may be able to join
- adult with a multiple sclerosis diagnosis,
- able to walk 50 meters without human help,
- Expanded Disability Status Scale (EDSS) < 7
Who cannot join
- relapse of multiple sclerosis in the last 7-days,
- acute urinary tract infection
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition for Patients With Multiple Sclerosis
The aim of the study is to create a specific test to assess the global time required to go to the toilet and to perform micturition, at the moment the patient decides to urinate in multiple sclerosis population, and to assess its reliability.
Read the detailed description
Lower urinary tract symptoms (LUTS) are frequent in central nervous system disorders especially in patients with multiple sclerosis (PwMS). Prevalence of LUTS is important (32 to 96.8%) and increases with the multiple sclerosis (MS) duration and the severity of the neurological deficiencies and disabilities. Overactive bladder with urgency, frequency, urge incontinence, is the most common symptom, reported by 37-99% of the PwMS. OAB not only impacts quality of life but overactive detrusor associated with detrusor sphincter dyssynergia can lead to upper urinary tract alteration (reflux, dilatation, urinary tract infection). In the absence of risk factor, the treatment aims to improve comfort and quality of life. Anticholinergic drugs are usually the first-line treatment, but their frequent adverse effects (constipation, xerostomia, cognitive impairment) may impact compliance and adherence. The warning time (defined as the time between the first desire to void and the micturition impossible to defer) only partially reflects the possibilities of continence. Indeed, other numerous and various factors such as patient mobility, autonomy for transfers, speed of undressing, etc., can influence the global time between the first alert (first desire to void) and the imperious micturition and thus on the risk of incontinence.
The global time required to go to the toilet and undress is difficult to quantify and no specific and validated test is available for this.
The aim of the study is to create a specific test to assess the global time required to go to the toilet and to perform micturition, at the moment the patient decides to urinate in multiple sclerosis population, and to assess its reliability.
In this study, the investigators develop a new tool to assess the global time required to go to the toilet until patients are ready to void: Time to be Ready to Void (TRV). The different stages to go to the toilet are individualized, and two prior steps are defined: a mobility stage starting when the examiner gives the starting signal, includes the stand up, the walk to the toilets, and stops when the patient puts his hand on the door handle; and a settled stage starting as soon as the subject has his hand on the door handle, until he is undressed and in his usual and secure position to void. The "interval" or "lap" function of the chronometer is used to facilitate the recording. Difficulty of each stage is assessed by a 4-point Likert type scale with 3 indicating ''no difficulty'' and 0 indicating ''impossible or necessitate human help".
This study was approved by the local ethics review board RCB: 2018-A01644-51. Participants will be recruited in a Neuro-urology department during a medical appointment, an urodynamic assessment, or a day hospital related to urinary disorders.
Data collected are:
- Medical history
- Age
- Sex
- EDSS score
- Urinary Symptom Profile score
- Data of the last urodynamic
- need to void with numerical scale between 0 and 10 before the test
To assess inter-rater reliability, two examiners record the first TRV try with both a digital chronometer. To assess reliability of the TRV, a second try is done after at least 10 minutes of rest, with one of the two examiners, checking that the need to void has not changed significantly.
To assess the internal consistency of the TRV, further tests are carried out:
- a 10-meter walk test (10MWT) at maximum speed
- a Timed Up and Go (TUG)
- a Tinetti Mobility Test
- the self-questionnaire Fall Efficacy Scale International for balance evaluation
- a bilateral Nine Hold Peg (NHP) Test for dexterity
- the Functional Independence Measure (FIM) score
- the Katz - activities of daily living index (Katz ADL)
Statistical analyses will be performed with the R software for Windows (Rx64 3.2.3, R Foundation for Statistical Computing, Vienna, Austria). Descriptive data will be presented as means with SD for continuous data and as medians with range for ordinal data and data not normally distributed.
Inter-rater reliability and test-re test reliability will be assessed using intra-class correlation coefficient (ICC, absolute agreement). Internal consistency with the complementary tests will be assessed using Spearman correlation.
- Being tested
- completion of the test created Time to be Ready to Void
- Medical subject headings
- Gait Disorders, Neurologic, Urinary Incontinence, Urge, Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
completion of the test created Time to be Ready to VoidOther
completion of the test created (Time to be Ready to Void) The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate
| Study group | Role | What they receive |
|---|---|---|
| Participants | adult with a multiple sclerosis diagnosis, able to walk 50 meters without human help, Expanded Disability Status Scale (EDSS) < 7, consulting in a neuro-urology department Receives: Other: completion of the test created Time to be Ready to Void |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total time for TRV
The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate. All the test is timed
Measured: 1 day
Secondary outcomes (2)
Time for the first stage: "mobility" stage
, the "mobility" stage, starting when the examiner gives the starting signal, includes the stand up, the walk to the toilets, and stops when the patient puts his hand on the door handle
Measured: 1 day
Time for the second stage: "settled" stage
the "settled" stage starts as soon as the subject has his hand on the door handle, until he is undressed and in his usual and secure position to void
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2019
- Study start13 Mar 2019
- Primary completion31 Jul 2019
- Study completion31 Jul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gait Disorders, NeurologicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gérard Amarenco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Gérard Amarenco, Pierre and Marie Curie University
- Investigators
- Gérard Amarenco, PhD, Principal investigator, Sorbonne Université, GRC 001, GREEN, AP-HP, Hôpital Tenon, Paris, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04024085
- Sponsor's protocol ID
- GRC-001 GREEN
- Status last verified
- Feb 2022
- First submitted
- 16 Jul 2019
- Last updated
- 18 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition for Patients With Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT04024085
- Acronym / sponsor ID
- GRC-001 GREEN
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Gérard AmarencoUniversity, hospital or other
- Study start
- 13 Mar 2019 (actual)
- Primary completion
- 31 Jul 2019 (actual)
- Study completion
- 31 Jul 2019 (actual)
- First posted
- 18 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to create a specific test to assess the global time required to go to the toilet and to perform micturition, at the moment the patient decides to urinate in multiple sclerosis population, and to assess its reliability.
Detailed description
Lower urinary tract symptoms (LUTS) are frequent in central nervous system disorders especially in patients with multiple sclerosis (PwMS). Prevalence of LUTS is important (32 to 96.8%) and increases with the multiple sclerosis (MS) duration and the severity of the neurological deficiencies and disabilities. Overactive bladder with urgency, frequency, urge incontinence, is the most common symptom, reported by 37-99% of the PwMS. OAB not only impacts quality of life but overactive detrusor associated with detrusor sphincter dyssynergia can lead to upper urinary tract alteration (reflux, dilatation, urinary tract infection). In the absence of risk factor, the treatment aims to improve comfort and quality of life. Anticholinergic drugs are usually the first-line treatment, but their frequent adverse effects (constipation, xerostomia, cognitive impairment) may impact compliance and adherence. The warning time (defined as the time between the first desire to void and the micturition impossible to defer) only partially reflects the possibilities of continence. Indeed, other numerous and various factors such as patient mobility, autonomy for transfers, speed of undressing, etc., can influence the global time between the first alert (first desire to void) and the imperious micturition and thus on the risk of incontinence.
The global time required to go to the toilet and undress is difficult to quantify and no specific and validated test is available for this.
The aim of the study is to create a specific test to assess the global time required to go to the toilet and to perform micturition, at the moment the patient decides to urinate in multiple sclerosis population, and to assess its reliability.
In this study, the investigators develop a new tool to assess the global time required to go to the toilet until patients are ready to void: Time to be Ready to Void (TRV). The different stages to go to the toilet are individualized, and two prior steps are defined: a mobility stage starting when the examiner gives the starting signal, includes the stand up, the walk to the toilets, and stops when the patient puts his hand on the door handle; and a settled stage starting as soon as the subject has his hand on the door handle, until he is undressed and in his usual and secure position to void. The "interval" or "lap" function of the chronometer is used to facilitate the recording. Difficulty of each stage is assessed by a 4-point Likert type scale with 3 indicating ''no difficulty'' and 0 indicating ''impossible or necessitate human help".
This study was approved by the local ethics review board RCB: 2018-A01644-51. Participants will be recruited in a Neuro-urology department during a medical appointment, an urodynamic assessment, or a day hospital related to urinary disorders.
Data collected are:
- Medical history
- Age
- Sex
- EDSS score
- Urinary Symptom Profile score
- Data of the last urodynamic
- need to void with numerical scale between 0 and 10 before the test
To assess inter-rater reliability, two examiners record the first TRV try with both a digital chronometer. To assess reliability of the TRV, a second try is done after at least 10 minutes of rest, with one of the two examiners, checking that the need to void has not changed significantly.
To assess the internal consistency of the TRV, further tests are carried out:
- a 10-meter walk test (10MWT) at maximum speed
- a Timed Up and Go (TUG)
- a Tinetti Mobility Test
- the self-questionnaire Fall Efficacy Scale International for balance evaluation
- a bilateral Nine Hold Peg (NHP) Test for dexterity
- the Functional Independence Measure (FIM) score
- the Katz - activities of daily living index (Katz ADL)
Statistical analyses will be performed with the R software for Windows (Rx64 3.2.3, R Foundation for Statistical Computing, Vienna, Austria). Descriptive data will be presented as means with SD for continuous data and as medians with range for ordinal data and data not normally distributed.
Inter-rater reliability and test-re test reliability will be assessed using intra-class correlation coefficient (ICC, absolute agreement). Internal consistency with the complementary tests will be assessed using Spearman correlation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants | – | Other: completion of the test created Time to be Ready to Voidadult with a multiple sclerosis diagnosis, able to walk 50 meters without human help, Expanded Disability Status Scale (EDSS) < 7, consulting in a neuro-urology department |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with multiple sclerosis who were consulting in neuro-urology department
Key inclusion criteria (3 listed)
- adult with a multiple sclerosis diagnosis,
- able to walk 50 meters without human help,
- Expanded Disability Status Scale (EDSS) < 7
Key exclusion criteria (2 listed)
- relapse of multiple sclerosis in the last 7-days,
- acute urinary tract infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| completion of the test created Time to be Ready to Voidcompletion of the test created (Time to be Ready to Void) The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate | Other | Participants |
Primary outcome
Total time for TRV
Time frame: 1 day
The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate. All the test is timed
2 secondary outcomes
Time for the first stage: "mobility" stage
Time frame: 1 day
Time for the second stage: "settled" stage
Time frame: 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Gait Disorders, Neurologic
Recruiting
Implant for Walking After Incomplete SCI
Spinal Cord Injury (SCI), Gait
RecruitingObservational study
Usability of the Smart Hallway System in Clinical Setting
Amputation, Gait Disorders, Neurologic
Not yet recruiting
Cognitive-Motor Training for Gait Adaptability in Parkinson Disease
Parkinson Disease
Active, not recruiting
Comparative Effects of Vestibular Rehabilitation With and Without Cervical JPS Training in Stroke Patients
Stroke
Recruiting
Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury
Spinal Cord Injuries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gérard Amarenco, PhD principal investigator
Sorbonne Université, GRC 001, GREEN, AP-HP, Hôpital Tenon, Paris, France
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gait Disorders, Neurologic and Urinary Incontinence, Urge, run by Gérard Amarenco at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total time for TRV (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2022.